Myeloid Malignancies: Myelodysplastic Syndromes, Myeloproliferative Disorders, and Acute Myeloid Leukemia

Clinics in Laboratory Medicine

Volumn 27, Issue 3, 2007, Pages 551-575

  Wood, Brent L ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CELL STRUCTURE; CYTOGENETICS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ANTIGENS, CD; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447559803     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2007.05.006     Document Type: Review

References (85)

1. Wood B. Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol 75 (2004) 559-576
2. Terstappen L.W., Safford M., and Loken M.R. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 4 9 (1990) 657-663
3. Terstappen L.W., and Loken M.R. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 2 4 (1990) 229-240
4. Terstappen L.W., Hollander Z., Meiners H., et al. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol 48 2 (1990) 138-148
5. Loken M.R., Shah V.O., Dattilio K.L., et al. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 69 1 (1987) 255-263
6. Wood B., and Borowitz M.J. The flow cytometric evaluation of hematopoietic neoplasia in Henry's clinical diagnosis and management by laboratory methods (2006), Saunders, Philadelphia
7. Kussick S.J., and Wood B.L. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 127 9 (2003) 1140-1147
8. Manz M.G., Miyamoto T., Akashi K., et al. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 99 18 (2002) 11872-11877
9. Yang D.T., Greenwood J.H., Hartung L., et al. Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations. Am J Clin Pathol 124 6 (2005) 930-936
10. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 81 (2007) 584-592
11. MacDonald K.P., Munster D.J., Clark G.J., et al. Characterization of human blood dendritic cell subsets. Blood 100 13 (2002) 4512-4520
12. Stetler-Stevenson M., Arthur D.C., Jabbour N., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98 4 (2001) 979-987
13. Wells D.A., Benesch M., Loken M.R., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102 1 (2003) 394-403
14. Kussick S.J., Fromm J.R., Rossini A., et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 124 2 (2005) 170-181
15. Kussick S.J., and Wood B.L. Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders. Am J Clin Pathol 120 6 (2003) 854-865
16. Wood B. 9-Color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130 5 (2006) 680-690
17. Jaffe E.S., Harris N.L., Stein H., et al. World Health Organization classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues (2001), IARC Press, Lyon (France)
18. Borowitz M.J., Guenther K.L., Shults K.E., et al. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 100 5 (1993) 534-540
19. Stelzer G.T., Shults K.E., and Loken M.R. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 677 (1993) 265-280
20. Ogata K., Nakamura K., Yokose N., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100 12 (2002) 3887-3896
21. Sternberg A., Killick S., Littlewood T., et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 106 9 (2005) 2982-2991
22. Cherian S., Moore J., Bantly A., et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 64 1 (2005) 9-17
23. Agis H., Krauth M.T., Bohm A., et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 125 2 (2006) 273-281
24. Matsushima T., Handa H., Yokohama A., et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 101 9 (2003) 3386-3390
25. Wilkinson K., Velloso E.R., Lopes L.F., et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 102 12 (2003) 4187-4190
26. Tefferi A., Patnaik M.M., and Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133 5 (2006) 468-492
27. Terstappen L.W., Safford M., Konemann S., et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 6 1 (1992) 70-80
28. Khalidi H.S., Medeiros L.J., Chang K.L., et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol 109 2 (1998) 211-220
29. Terstappen L.W., Safford M., Unterhalt M., et al. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 6 10 (1992) 993-1000
30. Jamieson C.H., Weissman I.L., and Passegue E. Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell 6 6 (2004) 531-533
31. van Rhenen A., Feller N., Kelder A., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11 18 (2005) 6520-6527
32. Ogata K., Kishikawa Y., Satoh C., et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108 3 (2006) 1037-1044
33. Elghetany M.T. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 83 12 (1998) 1104-1115
34. Elghetany M.T. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 99 1 (2002) 391-392
35. Bowen K.L., and Davis B.H. Abnormal patterns of expression of CD16 (FcR-III) and CD11b (CRIII) in the bone marrow of patients with myelodysplastic syndrome. Laboratory Hematolology 3 (1997) 292-298
36. Chang C.C., and Cleveland R.P. Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. Arch Pathol Lab Med 124 8 (2000) 1152-1156
37. Davis B.H., Olsen S.H., Ahmad E., et al. Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch Pathol Lab Med 130 5 (2006) 654-661
38. Mann K.P., DeCastro C.M., Liu J., et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 107 6 (1997) 653-660
39. Stroncek D.F., Jaszcz W., Herr G.P., et al. Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor. Transfusion 38 7 (1998) 663-668
40. Hansen I., Meyer K., and Hokland P. Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Eur J Haematol 61 5 (1998) 339-346
41. Malcovati L., Della Porta M.G., Lunghi M., et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 19 5 (2005) 776-783
42. Della Porta M.G., Malcovati L., Invernizzi R., et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 20 4 (2006) 549-555
43. Kuiper-Kramer P.A., Huisman C.M., Van der Molen-Sinke J., et al. The expression of transferrin receptors on erythroblasts in anaemia of chronic disease, myelodysplastic syndromes and iron deficiency. Acta Haematol 97 3 (1997) 127-131
44. Leinoe E.B., Hoffmann M.H., Kjaersgaard E., et al. Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia. Br J Haematol 127 1 (2004) 76-84
45. Handa M., Watanabe K., Kawai Y., et al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 73 3 (1995) 521-528
46. Jensen M.K., de Nully Brown P., Lund B.V., et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 110 1 (2000) 116-124
47. Griesshammer M., Beneke H., Nussbaumer B., et al. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 96 3 (1999) 191-196
48. Li J., Xia Y., and Kuter D.J. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol 111 3 (2000) 943-953
49. Baatout S., Chatelain B., Staquet P., et al. Endomitotic index of megakaryocytes measured by flow cytometry helps to diagnose hematological disorders with abnormal platelet counts. Anticancer Res 18 5A (1998) 3347-3353
50. Jacobsson S., Carneskog J., Ridell B., et al. Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Eur J Haematol 56 5 (1996) 287-292
51. Helleberg C., Knudsen H., Hansen P.B., et al. CD34+ megakaryoblastic leukaemic cells are CD38-, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7?. Leukemia 11 6 (1997) 830-834
52. Karandikar N.J., Aquino D.B., McKenna R.W., et al. Transient myeloproliferative disorder and acute myeloid leukemia in down syndrome. An immunophenotypic analysis. Am J Clin Pathol 116 2 (2001) 204-210
53. Amin M.B., Maeda K., Carey J.L., et al. Megakaryoblastic termination of myeloproliferative disorders. Henry Ford Hosp Med J 40 1-2 (1992) 122-126
54. Betz S.A., Foucar K., Head D.R., et al. False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. Blood 79 9 (1992) 2399-2403
55. Maynadie M., Picard F., Husson B., et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 100 7 (2002) 2349-2356
56. Del Canizo M.C., Fernandez M.E., Lopez A., et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 88 4 (2003) 402-407
57. Arroyo J.L., Fernandez M.E., Hernandez J.M., et al. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 5 3 (2004) 227-233
58. Orfao A., Ortuno F., de Santiago M., et al. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 58 1 (2004) 62-71
59. Weir E.G., and Borowitz M.J. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 38 2 (2001) 124-138
60. Macedo A., Orfao A., Gonzalez M., et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 9 6 (1995) 993-998
61. Macedo A., Orfao A., Vidriales M.B., et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 70 4 (1995) 189-194
62. Bradstock K., Matthews J., Benson E., et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 84 4 (1994) 1220-1225
63. Reading C.L., Estey E.H., Huh Y.O., et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 81 11 (1993) 3083-3090
64. Bene M.C., Castoldi G., Knapp W., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9 10 (1995) 1783-1786
65. Hrusak O., and Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 16 7 (2002) 1233-1258
66. Porwit-MacDonald A., Janossy G., Ivory K., et al. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 87 3 (1996) 1162-1169
67. Orfao A., Chillon M.C., Bortoluci A.M., et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 84 5 (1999) 405-412
68. Krasinskas A.M., Wasik M.A., Kamoun M., et al. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol 110 6 (1998) 797-805
69. Kern W., Danhauser-Riedl S., Ratei R., et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 88 6 (2003) 646-653
70. San Miguel J.F., Vidriales M.B., Lopez-Berges C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98 6 (2001) 1746-1751
71. Coustan-Smith E., Ribeiro R.C., Rubnitz J.E., et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 123 2 (2003) 243-252
72. Venditti A., Buccisano F., Del Poeta G., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96 12 (2000) 3948-3952
73. Venditti A., Maurillo L., Buccisano F., et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 17 11 (2003) 2178-2182
74. Buccisano F., Maurillo L., Gattei V., et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20 10 (2006) 1783-1789
75. Kern W., Voskova D., Schoch C., et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104 10 (2004) 3078-3085
76. Feller N., van der Pol M.A., van Stijn A., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18 8 (2004) 1380-1390
77. Sievers E.L., Lange B.J., Alonzo T.A., et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective children's cancer group study of 252 patients with acute myeloid leukemia. Blood 101 9 (2003) 3398-3406
78. Sievers E.L., Lange B.J., Buckley J.D., et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 88 20 (1996) 1483-1488
79. Langebrake C., Brinkmann I., Teigler-Schlegel A., et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 63 1 (2005) 1-9
80. Voskova D., Schoch C., Schnittger S., et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 62 1 (2004) 25-38
81. Baer M.R., Stewart C.C., Dodge R.K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97 11 (2001) 3574-3580
82. Bacher U., Kern W., Schoch C., et al. Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 106 4 (2006) 839-847
83. Langebrake C., Creutzig U., Dworzak M., et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 24 22 (2006) 3686-3692
84. van Stijn A., Feller N., Kok A., et al. Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clin Cancer Res 11 7 (2005) 2540-2546
85. Kern W., Voskova D., Schoch C., et al. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 89 5 (2004) 528-540